MAXALTLYO 10 mg, lyophilizate oral 6 oral lyophilisates
Active ingredients: Rizatriptan benzoate, Rizatriptan
Commercialized according to BDPMDispensing in France: Prescription only
Lyophilizate6 oral lyophilisatesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- MAXALTLYO 10 mg, lyophilisat oral
- Pharmaceutical form
- lyophilisat
- Route of administration
- orale
- Presentation description
- plaquette(s) aluminium PVC PVDC de 6 lyophilisat(s) suremballée(s)/surpochée(s)
- Marketing authorisation holder
- ORGANON FRANCE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 2 Nov 2009
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69922564CIP73479434CIP133400934794346Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| RIZATRIPTANlyophilisat | 10 mg · un lyophilisat | FT |
| BENZOATE DE RIZATRIPTANlyophilisat | 14,53 mg · un lyophilisat | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.